MDxHealth SA banner
M

MDxHealth SA
F:O6C

Watchlist Manager
MDxHealth SA
F:O6C
Watchlist
Price: 3.075 EUR Market Closed
Market Cap: €8.6m

Wall St Price Targets

O6C Price Targets Summary
MDxHealth SA

Wall Street analysts forecast O6C stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for O6C is 11.547 EUR with a low forecast of 9.271 EUR and a high forecast of 14.457 EUR.

Lowest Forecast
Price Target
9.271 EUR
201% Upside
Average Forecast
Price Target
11.547 EUR
276% Upside
Highest Forecast
Price Target
14.457 EUR
370% Upside
MDxHealth SA Competitors:
Price Targets
ZNTL
Zentalis Pharmaceuticals Inc
51% Upside
VERK
Verkkokauppa.com Oyj
37% Upside
ADSK
Autodesk Inc
33% Upside
RLMD
Relmada Therapeutics Inc
89% Upside

Revenue
Forecast

27% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
27% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 4 years is 22%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is O6C's stock price target?
Price Target
11.547 EUR

According to Wall Street analysts, the average 1-year price target for O6C is 11.547 EUR with a low forecast of 9.271 EUR and a high forecast of 14.457 EUR.

What is the Revenue forecast for MDxHealth SA?
Projected CAGR
22%

Over the last 14 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 4 years is 22%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett